Le zona – Partie 3 : la prévention du zona et des névralgies post-zostériennes

Lang, 2021, Vaccination for quality of life: herpes-zoster vaccines, Aging Clin Exp Res, 33, 1113, 10.1007/s40520-019-01374-5 Weinberg, 2009, Varicella-zoster virus specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine, J Infect Dis, 200, 1068, 10.1086/605611 Aspinall, 2018, Vaccination choices for older people, looking beyond age specific approaches, Expert Rev Vaccines, 17, 23, 10.1080/14760584.2018.1411197 Maia, 2021, Increased number of herpes-zoster cases in Brazil related to the COVID-19 pandemic, Int J Infect Dis, 104, 732, 10.1016/j.ijid.2021.02.033 Préta, 2022, Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b and mRNA-1273), Brit J Clin Pharmacol, 88, 3529, 10.1111/bcp.15280 Ferahta, 2016, Les vaccins contre le zona : efficacité, sécurité et rapport coût/bénéfices, Presse Med, 45, 162, 10.1016/j.lpm.2015.10.015 Dooling, 2018, Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines, Am J Transplant, 18, 756, 10.1111/ajt.14683 Chiyaka, 2019, Cost-effectiveness of herpes zoster vaccination: a systematic review, Pharmacoeconomics, 37, 169, 10.1007/s40273-018-0735-1 Choi, 2019, Immunogenicity of the varicella-zoster vaccine in community-dwelling non-robust elderly compare to robust elderly: a prospective cohort study, J Gerontol A Biol Sci Med Sci, 74, 1225, 10.1093/gerona/gly287 Levin, 2008, Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine, J Infect Dis, 197, 825, 10.1086/528696 Vesikari, 2013, Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules, Hum Vaccin Immunother, 9, 858, 10.4161/hv.23412 Duncan, 2015, Varicella zoster virus immunity: A primer, J Infect Dis, 71, S47 Tilden, 1986, Demonstration of NK cell mediated lysis of varicella-zoster virus (VZV)-infected cells: characterization of the effector cells, J Immunol, 136, 4243, 10.4049/jimmunol.136.11.4243 Cunningham, 2018, Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older, J Infect Dis, 217, 1750, 10.1093/infdis/jiy095 Lecrenier, 2018, Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention, Expert Rev Vaccines, 17, 619, 10.1080/14760584.2018.1495565 Levin, 2019, Immune responses to zoster vaccines, Hum Vaccin Immunother, 15, 772, 10.1080/21645515.2018.1560918 Strezova, 2022, Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination, Open Forum Infect Dis, 9, ofac485, 10.1093/ofid/ofac485 Marra, 2022, Prevention of herpes zoster: a focus on the effectiveness and safety of herpes zoster vaccines, Viruses, 14, 2667, 10.3390/v14122667 Kim, 2023, Clinical effectiveness of zoster vaccine live in kidney transplant recipients immunized prior to transplantation: a retrospective single-center cohort study, Clin Microbiol Infect, 10.1016/j.cmi.2023.02.014 Oxman, 2005, A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N Engl J Med, 352, 2271, 10.1056/NEJMoa051016 Levin, 2013, Varicella-zoster virus-specific antibody responses in 50–59-year-old recipients of zoster vaccine, J Infect Dis, 208, 1386, 10.1093/infdis/jit342 Oxman, 2008, Vaccination against herpes zoster and postherpetic neuralgia, J Infect Dis, 197, S228, 10.1086/522159 Schmader, 2012, Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years, Clin Infect Dis, 54, 922, 10.1093/cid/cir970 Schmader, 2012, Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy, Clin Infect Dis, 55, 1320, 10.1093/cid/cis638 Morrison, 2015, Long-term persistence of zoster vaccine efficacy, Clin Infect Dis, 60, 900, 10.1093/cid/ciu918 Leroux-Roels, 2012, A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults, J Infect Dis, 206, 1280, 10.1093/infdis/jis497 Chlibek, 2013, Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age, J Infect Dis, 208, 1953, 10.1093/infdis/jit365 Lal, 2015, Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults, N Engl J Med, 372, 2087, 10.1056/NEJMoa1501184 Cunningham, 2016, Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older, N Engl J Med, 375, 1019, 10.1056/NEJMoa1603800 Tricco, 2018, Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis, BMJ, 363, k4029, 10.1136/bmj.k4029 Therapeutics initiative, 2018, Systematic review report: Efficacy and safety of adjuvanted herpes zoster subunit vaccine, Evidence based drug therapy Wyman, 2013, Concomitant administration of pneumococcal-23 and zoster vaccines provides adequate herpes zoster coverage, Ann Pharmacother, 47, 1064, 10.1345/aph.1R742 Tseng, 2011, Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine, Vaccine, 29, 3628, 10.1016/j.vaccine.2011.03.018 MacIntyre, 2010, Concomitant administration of zoster and pneumococcal vaccines in adults ≥ 60 years old, Hum Vaccin Immunother, 6, 894, 10.4161/hv.6.11.12852 Lang, 2014, Vaccination in the elderly: What can be recommended?, Drugs Aging, 31, 581, 10.1007/s40266-014-0193-1 Simberkoff, 2010, Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial, Ann Intern Med, 152, 545, 10.7326/0003-4819-152-9-201005040-00004 Tseng, 2014, Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine, Clin Infect Dis, 58, 1125, 10.1093/cid/ciu058 Charkoudian, 2011, Acute retinal necrosis after herpes zoster vaccination, Arch Ophthalmol, 129, 1495, 10.1001/archophthalmol.2011.320 Le, 2017, Notes from the field: hospital contact investigation for a patient who developed a zoster vaccine-related rash – Maryland, February 2015, MMWR Morb Mortal Wkly Rep, 66, 763, 10.15585/mmwr.mm6628a6 Anderson, 2022, Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the advisory committee on immunization practices — United States, 2022, MMWR Morb Mortal Wkly Rep, 71, 80, 10.15585/mmwr.mm7103a2 Zanetti, 2022, Note de cadrage. Stratégie de prévention du zona: recommandation vaccinale 2022, HAS, 66, 763 Commission fédérale pour les vaccinations., 2021 Confédération Suisse, 2023 Baeyens, 2009, Willingness to vaccinate and to be vaccinated in adults, Aging Clin Exp Res, 21, 244, 10.1007/BF03324913 Lang, 2023, Le zona – Partie 1 : la phase aiguë, Neurol Psychiatr Geriatr, 23 Lang, 2023, Le zona – Partie 2 : les névralgies post-zostériennes, Neurol Psychiatr Geriatr, 23